Soo et al., 2004, (23) Hong Kong | Retrospective cohort | Hospital-admitted patients with SARS-CoV | 200–400 mL of CP (titre 1:160–1:2560) | Methylprednisolone (≥ 4 doses; each dose is a 500-mg pulse) | CP arm: n = 19 Control arm: n = 21 | CP arm: mean 38.7 (SD 12.39) Control arm: mean 47.9 (SD 19.6) | NR | NR |
Hung et al., 2013, (24) Hong Kong | RCT | Hospital-admitted patients with H1N1 influenza | Single infusion of 0.4 g/kg of H-IVIG solution over 4 hr; NAbT > 1:40 | 0.4 g/kg normal IVIG prepared by pharmacists; NAbT < 1:10 | CP arm: n = 17 Control arm: n = 18 | CP arm: 43 (36.5 to 56) Control arm: 52 (40.5 to 58.5) | APACHE II; CP arm: 12 (8 to 17.5) Control arm: 13 (9 to 19) | CP arm: 2 (1 to 4) Control arm: 3 (2 to 5) |
Beigel et al., 2017, (25) US | RCT | Hospital-admitted patients with influenza A (H1N1, H3N2), influenza B | 2 units of CP infusion with at least 1-hr gap | Standard care that included a neuraminidase inhibitor | CP arm: n = 49 Control arm: n = 49 | CP arm: 50 (38 to 66) Control arm: 57 (39 to 71) | APACHE II; CP arm: 11 (8 to 21) Control arm: 16 (10 to 22) | CP arm: 3 (2 to 5) Control arm: 4 (2 to 6) |
Beigel et al., 2019, (26) US | RCT | Hospital-admitted patients with influenza A (H1N1, H3N2) | 2 units high-titre anti-influenza plasma (hemagglutination inhibition titre ≥ 1:80) | 2 units of low titre plasma (hemagglutination inhibition titre, ≤ 1:10) | CP arm: n = 91 Control arm: n = 47 | CP arm: 43 (36.5 to 56) Control arm: 52 (40.5 to 58.5) | NEWS; CP arm: 5 (4 to 8) Control arm: 5 (3 to 7) PELOD score; CP arm: 0 (0 to 1) Control arm: 3 (1.5 to 12) | CP arm: 3 (2 to 5) Control arm: 3 (2 to 4) |
Davey et al., 2019, (27) multi-national | RCT | Hospital-admitted patients with influenza A (H1N1, H3N2), influenza B | Single infusion 25 g/kg H-IVIG (up to 24.75 g in saline (500 mL) over 2 hr | Saline placed in 500-mL bag (coloured sleeve) | CP arm: n = 156 Control arm: n = 152 | CP arm: 55 (41 to 68) Control arm: 57 (48 to 68) | NEWS; CP arm: 4 (2 to 6) Control arm: 4 (2 to 6) | CP arm: 3 (2 to 5) Control arm: 4 (2 to 5) |
van Griensven et al., 2016, (28) Guinea | Prospective non-randomized study | Laboratory-confirmed Ebola virus disease | 2 infusions 200–250 mL ABO-compatible CP (gap of 2 d) | Standard care without CP | CP arm: n = 99 Control arm: n = 418 | CP arm: 29 (0 to 75) Control arm: 28 (0 to 87) | NR | CP arm: 19% with > 6 d Control arm: 49% with > 6 d |